Recherche avancée

Karl-Ludwig Kley est un homme d'affaires allemand qui a été à la tête de 7 entreprises différentes. Il occupe le poste de président du conseil de surveillance de E.ON SE, de président du conseil de surveillance de Deutsche Lufthansa AG et de codirecteur de Glasbau Hahn GmbH. M. Kley est également membre du conseil d'administration de Bayerische Motoren Werke AG, de Fritz Thyssen Stiftung et de Deutsche Akademie der Technikwissenschaften eV, ainsi que président du conseil d'administration de Baden Badener Unternehmergesprche, vice-président de Bundesverband der Deutschen Industrie e.V., membre du conseil exécutif de E. Merck KG et vice-président de Verband der Chemischen Industrie eV.
Au cours de sa carrière, M. Kley a été président du conseil d'administration de Merck KGaA, directeur des finances et des relations avec les investisseurs de Bayer AG et directeur financier de Bayer Holding Ltd. (une filiale de Bayer AG), président du conseil de surveillance de Lufthansa AirPlus Servicekarten GmbH, président du conseil de surveillance de 1. FC Kln GmbH & Co. KGaA, directeur du conseil d'administration de KG Allgemeine Leasing GmbH & Co. et chef de la division pharmaceutique de Bayer SpA.
Le Dr Kley a obtenu un doctorat, un diplôme d'études supérieures et un diplôme d'études supérieures de la Ludwig-Maximilians-Universitt Mnchen.

Karl-Ludwig Kamprath formerly worked at Deutsche Sparkassen Leasing AG & Co. KG, as Chairman-Supervisory Board, Kreissparkasse München Starnberg Ebersberg, as Chairman, Deutsche Leasing AG, as Chairman-Supervisory Board, LfA Förderbank Bayern, as Director-Management Board, BayernLB Holding AG, as Director, GTU Geothermie Unterschleißheim AG, as Director-Supervisory Board from 2010 to 2012, and Baader Bank AG, as Member-Supervisory Board from 2010 to 2018.

Nikolai Kley is the founder of two companies, FORMA Therapeutics, Inc. (founded in 2008) and Orionis Biosciences, Inc. (founded in 2015).
At FORMA Therapeutics, he held the title of VP-Biology & Head-Drug Discovery Research from 2008 to 2011.
At Orionis Biosciences, he held the titles of President, Chief Executive Officer & Director from 2015 to present, and currently holds the titles of Managing Director & Director at Orionis Biosciences BV since 2015 and Professor at Princeton University.
He previously worked at Bristol Myers Squibb Co. as a Principal, GPC Biotech AG as a Vice President, The General Hospital Corp.
as a Fellow, Genome Therapeutics Corp.
as a Vice President, and Harvard Medical School as a Fellow.
He received his undergraduate degree from the University of Leeds and doctorate degrees from Max-Planck-Institute for Molecular Genetics and Ludwig-Maximilians-Universität München.

Mr. Jason B.
Kley is Senior Integrated Wealth Advisor at Carlson Capital Management, Inc. He is a member of the Minnesota Financial Planning Association.
Before joining the CCM, Mr. Kley worked for a Minneapolis wealth management firm where he served as a financial advisor, investment committee member, and 401k plan specialist.
Prior to that, he worked for Thrivent Financial and Union Pacific, serving in business analyst and strategic operational roles.
Mr. Kley has also served on the Minneapolis Regional Chamber of Commerce DRIVE Emerging Leaders Board, Best Prep’s Minnesota Business Venture Advisory Committee, and the City of St. Louis Park Police Advisory Commission.
He holds a Bachelor of Arts degree in Math and Computer Science from the University of St. Thomas where he graduated magna cum laude in 1998.
He also earned an MBA with an emphasis in Finance and Strategy from Washington University in St. Louis, Missouri.

Karl-Ludwig Blocher has worked as a Co-Managing Director at Viimle GmbH since 2018.

Mr. Karl-Ludwig Soll is Chief Financial Officer at United Nations Joint Staff Pension Fund.
He joined the firm in January 2012.
Mr. Soll was previously employed as Senior Manager by KPMG LLP, a Principal by Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, and an Associate by Arthur Andersen & Co. GmbH.
He also served on the board at PricewaterhouseCoopers LLP.
Mr. Soll received his undergraduate degree from Freie Universität Berlin in 1992.

Karl-Ludwig Kaditzky currently works at Kliniken Südostbayern AG, as Member-Supervisory Board.

Karl-Ludwig Büdenbender is currently the Deputy Chairman-Supervisory Board at Volksbank Heuchelheim eG.

Michelle Kley is currently the Director at MDA Systems Ltd.
and a Member at the International Institute of Space Commerce.
She previously worked as the Secretary & Director at Maxar Intelligence, Inc., Vice President-Legal & Associate General Counsel at Maxar Space LLC, Secretary, Senior Vice President & General Counsel at Maxar Technologies ULC, Associate at Morrison & Foerster LLP, Associate at Wilson Sonsini Goodrich & Rosati PC, Legal Counsel at Beazley Group (USA) GP, SVP, Chief Legal & Compliance Officer at Maxar Technologies Holdings, Inc., and Secretary, Senior Vice President & General Counsel at Maxar Technologies, Inc. She also worked as the Secretary, Executive VP-Legal & General Counsel at Virgin Galactic Holdings, Inc. Ms. Kley holds an undergraduate degree from Sonoma State University and a graduate degree from Berkeley Law University of California.
She is currently the Secretary, Chief Legal Officer & Executive VP at Volta, Inc.

Jana Kley worked as a Director of Human Resources at Carrier Corp.
from 2005 to 2006, and then as a Director of Human Resources at Carrier Transicold France SAS from 2006 to 2010.
She later became the VP of HR for the Building & Industrial Systems Division at United Technologies Corp.
Ms. Kley also worked as the Executive Vice President of Human Resources at Plastic Omnium SE from 2021 to 2022, and as the VP of Human Resources & Communication, EMEA at Otis Elevator Co.

Eduard Hans-Jochen Kley is currently a Director at Enerjisa Enerji Üretim AS.
Previously, he served as the Chairman-Management Board & CEO at Zapadoslovenska Energetika as from 2013 to 2020.
He also worked as a Director at Enerjisa Enerji AS.

Max Dietrich Kley formerly worked at SGL Carbon SE, as Chairman in 2009, Infineon Technologies AG, as Chairman-Supervisory Board in 2010, UniCredit SpA, as Director in 2009, BASF SE, as Member-Supervisory Board from 1969 to 2010, Heidelberg Materials AG, as Membar-Supervisory Board in 2009, Rheinland-Pfalz Bank, as Member-Supervisory Board, and SCHOTT AG, as Member-Supervisory Board from 2004 to 2009.
Mr. Kley received his graduate degree from Ludwig-Maximilians-Universität München.

Max Gisbert Kley is currently the Chairman-Supervisory Board at Hemoteq AG and the Co-Managing Director at Freudenberg e-Power Systems GmbH.
Previously, he served as the President & Chief Executive Officer at Freudenberg Medical LLC from 2000 to 2022.

Jan van der Kley has held positions as Director at Biosciences Research & Commercialization Center and Treasurer & Trustee at Paper Technology Foundation, Inc.

Cornells A.
van der Kley served as a Non-Executive Director at Gunns Ltd.
from 1996 to 2008.